SeekingAlpha•2026-04-21
Travere Therapeutics: Still Undervalued Post FSGS ApprovalTVTX — Travere Therapeutics Inc
NASDAQ · Biotechnology · Biotechnology
$38.78+10.77%Market cap2.54B
- Latest Close
- $38.78
- 30-Day Move
- +10.8%
- Market Cap
- $2.5B
- Shares Outstanding
- 92,240,000
- P/B Ratio
- 29.77
- ROE
- -22.3%
Analyst consensus: Buy · 21 analysts
NASDAQ:TVTXBiotechnology / BiotechnologyDelayed public snapshot
Travere Therapeutics Inc
A read-only Alphactor snapshot forTravere Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$38.78
30-Day Move
+10.8%
Market Cap
$2.5B
Shares Outstanding
92,240,000
P/B Ratio
29.77
ROE
-22.3%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$38.78
+10.8%last 90 delayed daily bars
Market cap$2.5B
90D High
$43.31
90D Low
$22.59
Avg Volume
2,135,395
What stands out
Gross margin is running at 97.9%, which gives a quick read on operating quality before you open the full model.
Net margin is -5.2%, useful for comparing TVTX against peers in Biotechnology.
TVTX is up 10.8% over the last 30 trading days shown on this page.
Latest operating income is $-32M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$26.14
Rule of 40
106.3%
Dark Pool Short %
65.0%
Fundamentals snapshot
Latest Close
$38.78
30-Day Move
+10.8%
Market Cap
$2.5B
Shares Outstanding
92,240,000
P/B Ratio
29.77
ROE
-22.3%
ROA
-4.2%
Gross Margin
97.9%
Operating Margin
-12.8%
Net Margin
-5.2%
Debt / Equity
2.71
Current Ratio
2.74
Latest Revenue
$130M
Financial statement snapshot
Revenue
$130M
Gross Profit
$127M
Operating Income
$-32M
Net Income
$3M
Gross Margin
9789.0%
Net Margin
-521.0%
Current Ratio
2.74
Debt / Equity
2.71
Valuation snapshot
Fair Value
$26.14
Upside / Downside
-32.6%
Signal
Overvalued
Implied Growth
26.0%
DCF
$28.22
EV/Rev
$24.05
Growth Assumption
50.0%
Discount Rate
9.9%
Terminal Growth
2.0%
Base FCF
$38M
Valuation spread
Current Price
$38.78
Composite Fair Value
$26.14
DCF
$28.22
EV/Rev
$24.05
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Quality snapshot
Altman Z
0.72
Distress
Piotroski
7
Strong (7-9)
Cash Conversion
-1.48x
Rule of 40
106.3%
Elite
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $109M | $-320M | $-278M | $-215M |
| 2023-12-31 | $145M | $-377M | $-111M | $-322M |
| 2024-12-31 | $233M | $-321M | $-322M | $-339M |
| 2025-12-31 | $491M | $-63M | $-26M | $-20M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Benzinga•2026-04-16
First FDA-Approved Treatment For Patients With Focal Segmental Glomerulosclerosis, A Rare Kidney ConditionFinnhub•2026-04-16
Fda approves treatment for patients with focal segmental glomerulosclerosisSeekingAlpha•2026-04-15
Travere Therapeutics: Re-Rating Potential As Filspari Wins Full ApprovalAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 3,408,447 | 0.04% | 2026-02-28 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 3,153,195 | 0.03% | 2025-11-30 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2,996,248 | 0.03% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2,811,499 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 2,008,567 | 0.02% | 2026-02-28 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1,437,191 | 0.02% | 2025-12-31 |
| Vanguard Explorer Fund | 1,256,468 | 0.01% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 964,778 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
FMR LLC (Fidelity)
Filed 2026-02-17
$367M
+232.3%
Vanguard Group
Filed 2026-01-29
$241M
-4.6%
Renaissance Technologies
Filed 2026-02-12
$86M
+28.2%
Geode Capital Management
Filed 2026-02-09
$82M
+0.3%
Goldman Sachs
Filed 2026-02-10
$71M
+46.7%
BlackRock
Filed 2024-08-13
$63M
--
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.24
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
21
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.